Table 1. Application of DpR in colorectal cancer.

Patients	Regimen	Sample size	Outcomes	References
KRAS WT mCRC	Chemotherapy + cetuximab	841	Median DpR: FOLFIRI + cetuximab:50.9%, FOLFOX4 + cetuximab: 57.9%; higher DpR with longer PPS	(7)
KRAS WT mCRC	Chemotherapy + cetuximab	54	Median DpR 56.3%, correlation between DpR and outcomes (OS: rs=0.314, P=0.027; PPS: rs=0.366, P=0.017)	(19)
KRAS WT mCRC	Chemotherapy + cetuximab	92	Median DpR 50.4%, correlation between DpR and outcomes (PFS: rs=0.56, P<0.0001; OS: rs=0.39, P=0.0090)	(18)
KRAS WT mCRC	Chemotherapy + cetuximab	76	Median DpR 52%, DpR correlated with OS and PFS	(20)
KRAS WT mCRC	Chemotherapy + cetuximab	188	Median DpR: 48.9%, DpR correlated (P<0.0001) with OS	(21)
mCRC	Second-line Chemotherapy + cetuximab	112	FOLFIRI+cetuximab, correlation between DpR and outcomes (OS: r=0.51, P<0.001; PFS: r=0.54, P<0.001)	(22)
RAS WT mCRC	Chemotherapy + panitumumab	460	DpR ≥30% vs. <30%: mPFS (11.9 vs. 3.8 months, HR 3.25 (95% CI, 2.62–4.04); P<0.0001); mOS (30.3 vs. 9.4 months, HR 3.24 (95% CI, 2.59–4.05); P<0.0001)	(23,24)
KRAS WT mCRC	Chemotherapy + panitumumab	170	DpR ≥30% vs. <30%, mPFS [13.0 vs. 7.4 months, HR 2.80 (95% CI, 1.86–4.23); P<0.0001]; mOS (median 37.4 vs. 17.3 months, HR 3.08 (95% CI, 2.01–4.71); P<0.0001)	(23,25)
KRAS WT mCRC	Chemotherapy + panitumumab	53	Median DpR 48%, correlation between DpR and outcomes (PFS: Spearman Coefficient: =0.53, P<0.0001) (OS: Spearman Coefficient=0.51, P<0.0002)	(23,26)
mCRC	Chemotherapy	156	Median DpR 44.2%, DpR ≥45% vs. <45%, mPFS (16.4 vs. 8.1 months, P=0.006); mOS (58.6 vs. 30.9 months, P=0.041)	(27)
mCRC	Chemotherapy	242	Median DpR 38.5%, DpR ≥60% vs. <60%, PFS (11.6 vs. 4.8 months, P<0.001); PPS (18.4 vs. 10.1 months, P<0.001); OS (31.6 vs. 17.2 months; P<0.001)	(28)
mCRC	Chemotherapy + bevacizumab	508	FOLFOXIRI+bevacizumab vs. FOLFIRI+bevacizumab: (DpR: 43.4% vs. 37.8%, P=0.003); HR for PFS: 0.990 (95% CI, 0.986–0.993); HR for PPS: 0.984 (95% CI, 0.979–0.989); HR for OS: 0.988 (95% CI, 0.982–0.993)	(29)